Gene Editing to
Revolutionize Biotech

May 17, 2023

C4U Corporation has raised a total of 1.5 billion JPY (approximately $11 million at the then-effective exchange rate) for its Series B financing.
DCI Partners, Co., Ltd. who has been a lead investor since the Series A round in 2021, and other six investors including four new investors participated in this Series B round.
Since its establishment in March 2018, the accumulated funds have reached 2.6 billion JPY, and C4U plans to use the funds for further research and development of CRISPR-Cas3 system and its applications in a medical field, especially in vivo and ex vivo treatments.
In addition to the above, C4U is also seeking opportunities in any industrial fields.

March 15, 2023

Our researcher will give a poster presentation at the Keystone Symposia on Molecular and Cellular Biology "Precision Genome Engineering", in Whistler, Canada, from March 19-23, 2023.

October 28, 2022

C4U and Brain Research Institute, Niigata University have entered into the collaborative research agreement for a novel gene therapy utilizing CRISPR -Cas3 technology.

September 1, 2022

The paper “Dynamic mechanisms of CRISPR interference by Escherichia coli CRISPR-Cas3” was published in Nature Communications.

August 31, 2022

In addition to the current collaborative research and alliance agreement, C4U and Sumitomo Pharma identified additional target cells and genes for two regenerative medicine products respectively, and entered into a collaborative research and alliance agreement for each of them. These brought the total number of our collaborative research and alliance agreement between C4U and Sumitomo Pharma to three.

©2019 C4U Corporation